Breaking News Instant updates and real-time market news.

AGIO

Agios Pharmaceuticals

$37.87

0.51 (1.37%)

07:02
11/26/19
11/26
07:02
11/26/19
07:02

Agios Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young initiated coverage of Agios Pharmaceuticals with an Overweight rating and $64 price target. Although shares were under pressure in 2019, there are catalysts on the horizon and overhangs lifted like financing "that should clear the way for 2020 outperformance," Young tells investors in a research note. She believes Agios has a "robust R&D engine" focused on cellular metabolism and precision medicine for cancer and rare genetic diseases.

  • 07

    Dec

  • 13

    Dec

AGIO Agios Pharmaceuticals
$37.87

0.51 (1.37%)

10/01/19
RBCM
10/01/19
NO CHANGE
Target $82
RBCM
Outperform
Agios Pharmaceuticals price target lowered to $82 from $89 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Agios Pharmaceuticals to $82, reflecting the reduction of the Tibsovo treatment duration estimate of cholangiocarcinoma to 2.7 months. The analyst notes that he still sees potential to grow the "IDHmut" market with upside from earlier lines of therapy with longer treatment duration, adding that in the near term, his focus is on the initial clinical data from AG-270 in MTAP-deleted patients. MacKay adds that these trials could generate upside for the stock, keeping his Outperform rating on Agios Pharmaceuticals.
10/28/19
PIPR
10/28/19
NO CHANGE
Target $70
PIPR
Overweight
Agios Pharmaceuticals price target lowered to $70 from $80 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target for Agios Pharmaceuticals to $70 from $80 after initial clinical data from AG-270's methylthioadenosine phosphorylase program yielded low monotherapy activity, as expected. The analyst we believes it is prudent to remove AG-270 from his model. However, he keeps an Overweight rating on Agios saying the shares "are at a floor and that significant value can still be created" from mitapivat, DHODH, or eventually methylthioadenosine phosphorylase.
11/05/19
SBSH
11/05/19
NO CHANGE
Target $64
SBSH
Buy
Agios Pharmaceuticals price target lowered to $64 from $80 at Citi
Citi analyst Mohit Bansal lowered his price target for Agios Pharmaceuticals to $64 from $80 saying the company's announcement, based on the FDA feedback, to wait for overall survival data for filing makes him less confident in the cholangio approval. However, the analyst does not think the Street was giving much credit to cholangio. He keeps a Buy rating on Agios.
11/24/19
PIPR
11/24/19
NO CHANGE
PIPR
Overweight
Piper Jaffray reiterates Overweight on Agios after 'encouraging' SNO update
Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating and $70 price target on Agios following the company's "encouraging" IDH/glioma update at the Society for Neuro-Oncology, or SNO. The analyst believes the perioperative results are "promising" given the response and disease control rates observed, and believes the "high DCR suggests that IDH inhibition is proving a meaningful, durable treatment benefit." Van Buren said that this could ultimately become a $500M opportunity that is not currently modeled.

TODAY'S FREE FLY STORIES

09:58
12/09/19
12/09
09:58
12/09/19
09:58
Conference/Events
JPMorgan oil services/equip analyst to hold an analyst/industry conference call »

Oil Services &…

PCG

PG&E

$11.30

1.65 (17.10%)

, SIG

Signet Jewelers

$21.05

0.48 (2.33%)

09:55
12/09/19
12/09
09:55
12/09/19
09:55
Options
Early notable gainers among liquid option names on December 9th »

Notable gainers among…

PCG

PG&E

$11.30

1.65 (17.10%)

SIG

Signet Jewelers

$21.05

0.48 (2.33%)

SWKS

Skyworks

$104.20

2.8 (2.76%)

FCX

Freeport McMoRan

$11.97

0.33 (2.84%)

FTV

Fortive

$75.51

2.65 (3.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 07

    Jan

09:55
12/09/19
12/09
09:55
12/09/19
09:55
Conference/Events
JPMorgan homebuilding analyst to hold an analyst/industry conference call »

Homebuilding &…

09:55
12/09/19
12/09
09:55
12/09/19
09:55
Conference/Events
JPMorgan business services analyst to hold analyst/industry conference call »

Business &…

FTSV

Forty Seven

$17.61

3.21 (22.29%)

09:53
12/09/19
12/09
09:53
12/09/19
09:53
Hot Stocks
Breaking Hot Stocks news story on Forty Seven »

Forty Seven trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

TTWO

Take-Two

$119.55

-4.21 (-3.40%)

09:53
12/09/19
12/09
09:53
12/09/19
09:53
Recommendations
Take-Two analyst commentary  »

Take-Two's BioShock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

HY

Hyster-Yale Materials

$60.47

0.66 (1.10%)

09:52
12/09/19
12/09
09:52
12/09/19
09:52
Conference/Events
Hyster-Yale Materials management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 26

    Feb

ZS

Zscaler

$47.38

0.66 (1.41%)

09:50
12/09/19
12/09
09:50
12/09/19
09:50
Options
Funky call sale in ZScaler at market-open »

Funky call sale in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 16

    Dec

RTRX

Retrophin

$13.31

0.05 (0.38%)

09:50
12/09/19
12/09
09:50
12/09/19
09:50
Conference/Events
Retrophin management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ARQL

ArQule

$19.61

9.94 (102.79%)

, LLY

Eli Lilly

$119.52

-0.07 (-0.06%)

09:49
12/09/19
12/09
09:49
12/09/19
09:49
Conference/Events
Wolfe Research biotech analyst to hold an analyst/industry webcast »

Biotech Analyst Tewari…

ARQL

ArQule

$19.61

9.94 (102.79%)

LLY

Eli Lilly

$119.52

-0.07 (-0.06%)

MRK

Merck

$88.76

-0.08 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

  • 17

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 05

    Feb

  • 14

    Mar

XFOR

X4 Pharmaceuticals

$10.60

(0.00%)

09:48
12/09/19
12/09
09:48
12/09/19
09:48
Upgrade
X4 Pharmaceuticals rating change  »

X4 Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$15.86

1.46 (10.14%)

09:48
12/09/19
12/09
09:48
12/09/19
09:48
Hot Stocks
Breaking Hot Stocks news story on Forty Seven »

Forty Seven trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

KOS

Kosmos

$5.41

-0.62 (-10.28%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
Kosmos falls -10.6% »

Kosmos is down -10.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$7.93

-1.42 (-15.19%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
VelocityShares 3x Long Natural Gas ETN falls -15.2% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$3.97

-1.855 (-31.87%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
Diplomat Pharmacy falls -31.7% »

Diplomat Pharmacy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPCE

Virgin Galactic

$8.04

0.76 (10.44%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
Virgin Galactic rises 10.4% »

Virgin Galactic is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PCG

PG&E

$11.05

1.4 (14.51%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
PG&E rises 14.7% »

PG&E is up 14.7%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$180.50

24.71 (15.86%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN rises 16.0% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBB

RBB Bancorp

$20.42

(0.00%)

09:45
12/09/19
12/09
09:45
12/09/19
09:45
Conference/Events
RBB Bancorp management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

09:45
12/09/19
12/09
09:45
12/09/19
09:45
General news
Treasury 3-year auction outlook: the $38 B sale leads off »

Treasury 3-year auction…

TTWO

Take-Two

$123.76

(0.00%)

09:44
12/09/19
12/09
09:44
12/09/19
09:44
Hot Stocks
Take-Two says newly-formed 'Cloud Chamber' studio developing next BioShock game »

2K, a publishing label of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

ALPN

Alpine Immune Sciences

$3.02

(0.00%)

09:40
12/09/19
12/09
09:40
12/09/19
09:40
Hot Stocks
Alpine Immune Sciences presents ALPN-101 Phase 1 healthy volunteer study data »

Alpine Immune Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.03

(0.00%)

, SPCE

Virgin Galactic

$7.28

(0.00%)

09:40
12/09/19
12/09
09:40
12/09/19
09:40
Options
Unusually active option classes on open December 9th »

Unusual total active…

JBLU

JetBlue

$19.03

(0.00%)

SPCE

Virgin Galactic

$7.28

(0.00%)

CHWY

Chewy

$24.93

(0.00%)

VLO

Valero

$93.62

(0.00%)

DELL

Dell Technologies

$47.09

(0.00%)

CRWD

Crowdstrike

$50.89

(0.00%)

ZS

Zscaler

$46.72

(0.00%)

LULU

Lululemon

$229.50

(0.00%)

CGC

Canopy Growth

$18.65

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 16

    Dec

  • 27

    Feb

  • 09

    Dec

KALV

KalVista

$14.36

0.25 (1.77%)

, MRK

Merck

$88.84

0.09 (0.10%)

09:37
12/09/19
12/09
09:37
12/09/19
09:37
Recommendations
KalVista, Merck analyst commentary  »

Roth says KalVista trial…

KALV

KalVista

$14.36

0.25 (1.77%)

MRK

Merck

$88.84

0.09 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

PSTL

Postal Realty Trust

$15.85

0.15 (0.96%)

09:34
12/09/19
12/09
09:34
12/09/19
09:34
Conference/Events
Postal Realty Trust management to meet with DA Davidson »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.